{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=69",
    "query": {
      "condition": "Solid Tumor Malignancies, Cancer",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 5458,
    "total_pages": 546,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=70&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumor+Malignancies%2C+Cancer&page=68&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T20:04:43.695Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07541573",
      "title": "GTB-5550 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tri-specific Killer Engager",
        "Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "GTB-5550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2026-04-08",
      "completion_date": "2032-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07541573"
    },
    {
      "nct_id": "NCT04504942",
      "title": "Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Leronlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-05-01",
      "completion_date": "2025-01-27",
      "has_results": true,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504942"
    },
    {
      "nct_id": "NCT06724926",
      "title": "Concurrent Azeliragon With Craniospinal Irradiation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "High-grade Glioma",
        "Leptomeningeal Metastasis"
      ],
      "interventions": [
        {
          "name": "Azeliragon",
          "type": "DRUG"
        },
        {
          "name": "CSI",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2025-02-18",
      "completion_date": "2031-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06724926"
    },
    {
      "nct_id": "NCT03813615",
      "title": "Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Preoperative Aerobic Training",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "treadmill walking (Proof-of-Concept)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "treadmill walking Dose-Finding / Escalation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2019-01-21",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03813615"
    },
    {
      "nct_id": "NCT07224425",
      "title": "A Study of BI 3810944 in Patients With Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumours",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "BI 3810944",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2026-02-24",
      "completion_date": "2029-10-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 4,
      "location_summary": "Louisville, Kentucky • Nashville, Tennessee • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224425"
    },
    {
      "nct_id": "NCT02001623",
      "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovary Cancer",
        "Cervix Cancer",
        "Endometrium Cancer",
        "Bladder Cancer",
        "Prostate Cancer (CRPC)",
        "Esophagus Cancer",
        "Lung Cancer(NSCLC)",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
      ],
      "interventions": [
        {
          "name": "Tisotumab Vedotin (HuMax-TF-ADC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 195,
      "start_date": "2013-11-30",
      "completion_date": "2019-05-02",
      "has_results": true,
      "last_update_posted_date": "2021-12-29",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 8,
      "location_summary": "Orange, California • New Haven, Connecticut • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02001623"
    },
    {
      "nct_id": "NCT05052268",
      "title": "XTX202 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "XTX202",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xilio Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2022-01-18",
      "completion_date": "2025-03-25",
      "has_results": true,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 11 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05052268"
    },
    {
      "nct_id": "NCT00258440",
      "title": "Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anemia",
        "Fatigue",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "Weekly procrit dosing",
          "type": "DRUG"
        },
        {
          "name": "Interval Dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2003-05",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258440"
    },
    {
      "nct_id": "NCT05572684",
      "title": "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Microsatellite Instability Low",
        "Microsatellite Instability High",
        "Microsatellite Stable",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Colo-rectal Cancer",
        "Esophageal Cancer",
        "Endometrial Cancer",
        "Head Neck Cancer",
        "Cervical Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NC410",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NextCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2022-10-06",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05572684"
    },
    {
      "nct_id": "NCT01369433",
      "title": "A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Tivozanib + paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Tivozanib + temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tivozanib",
          "type": "DRUG"
        },
        {
          "name": "Tivozanib (AV-951)",
          "type": "DRUG"
        },
        {
          "name": "Tivozanib + capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Tivo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2010-06",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-10-28T20:04:43.695Z",
      "location_count": 27,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Stanford, California + 24 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369433"
    }
  ]
}